La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

All Cosmos Bio-Tech Holding Bilan de santé

Santé financière contrôle des critères 5/6

All Cosmos Bio-Tech Holding possède un total de capitaux propres de NT$2.8B et une dette totale de NT$549.6M, ce qui porte son ratio d'endettement à 19.5%. Son actif total et son passif total sont NT$3.7B et de NT$879.5M. L'EBIT de All Cosmos Bio-Tech Holding est NT$151.3M ce qui fait que son ratio de couverture des intérêts -5. Elle dispose de liquidités et de placements à court terme de NT$1.6B.

Informations clés

19.4%

Ratio d'endettement

NT$555.01m

Dette

Ratio de couverture des intérêts	-4.3x
Argent liquide	NT$1.64b
Fonds propres	NT$2.86b
Total du passif	NT$895.38m
Total des actifs	NT$3.75b

Mises à jour récentes de la santé financière

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Apr 20

Recent updates

There May Be Reason For Hope In All Cosmos Bio-Tech Holding's (TWSE:4148) Disappointing Earnings

Mar 22

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Apr 20

Returns On Capital At All Cosmos Bio-Tech Holding (TPE:4148) Paint An Interesting Picture

Jan 10

All Cosmos Bio-Tech Holding Corporation's (TPE:4148) Price Is Out Of Tune With Earnings

Dec 22

Are Poor Financial Prospects Dragging Down All Cosmos Bio-Tech Holding Corporation (TPE:4148 Stock?

Dec 01

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4148 ( NT$2.8B ) dépassent ses passifs à court terme ( NT$816.0M ).

Passif à long terme: Les actifs à court terme de 4148 ( NT$2.8B ) dépassent ses passifs à long terme ( NT$63.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4148 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 4148 est passé de 10.7% à 19.5% au cours des 5 dernières années.

Couverture de la dette: La dette de 4148 est bien couverte par le flux de trésorerie opérationnel ( 125% ).

Couverture des intérêts: 4148 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

All Cosmos Bio-Tech Holding Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.12 (vs NT$0.61 in 2Q 2023)

All Cosmos Bio-Tech Holding Corporation to Report Q2, 2024 Results on Aug 27, 2024

Upcoming dividend of NT$1.00 per share

First quarter 2024 earnings released: EPS: NT$0.44 (vs NT$0.63 in 1Q 2023)

Dividend of NT$1.00 announced

All Cosmos Bio-Tech Holding Corporation to Report Q1, 2024 Results on May 13, 2024

New minor risk - Market cap size

All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024

There May Be Reason For Hope In All Cosmos Bio-Tech Holding's (TWSE:4148) Disappointing Earnings

Full year 2023 earnings released: EPS: NT$2.18 (vs NT$5.75 in FY 2022)

All Cosmos Bio-Tech Holding Corporation Announces the Retirement of Ling Siu Hung as Chief Operating Officer

Investor sentiment improves as stock rises 17%

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$2.48 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.61 (vs NT$1.47 in 2Q 2022)

New minor risk - Market cap size

Upcoming dividend of NT$2.50 per share at 4.1% yield

Full year 2022 earnings released: EPS: NT$5.75 (vs NT$3.09 in FY 2021)

Investor sentiment improves as stock rises 16%

Third quarter 2022 earnings released: EPS: NT$2.48 (vs NT$0.76 in 3Q 2021)

High number of new directors

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: NT$1.47 (vs NT$0.66 in 2Q 2021)

High number of new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

All Cosmos Bio-Tech Holding Corporation Announces Change in Remuneration Committee

All Cosmos Bio-Tech Holding Corporation Approves Cash Dividends for 2021

Upcoming dividend of NT$1.50 per share

First quarter 2022 earnings released: EPS: NT$1.07 (vs NT$0.42 in 1Q 2021)

Investor sentiment deteriorated over the past week

Price target increased to NT$102

Less than half of directors are independent

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: NT$3.09 (vs NT$1.28 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.76 (vs NT$0.54 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS NT$0.66 (vs NT$0.60 in 2Q 2020)

Upcoming dividend of NT$1.00 per share

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.41 loss in 1Q 2020)

All Cosmos Bio-Tech Holding Corporation Announces Cash Dividend, Payable on July 30, 2021

Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?

Price target decreased to NT$40.00

Acting for the Malaysian Subsidiary All Cosmos Bio-Tech Holding Corporation to Announce Temporary Shutdown of the Production Department

Returns On Capital At All Cosmos Bio-Tech Holding (TPE:4148) Paint An Interesting Picture

New 90-day high: NT$39.40

All Cosmos Bio-Tech Holding Corporation's (TPE:4148) Price Is Out Of Tune With Earnings

Are Poor Financial Prospects Dragging Down All Cosmos Bio-Tech Holding Corporation (TPE:4148 Stock?

Third quarter 2020 earnings released: EPS NT$0.54

New 90-day low: NT$33.80

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines